Company intelligence / Profile preview

HepaRegeniX GmbH

Ownership: Private
Development stage: Phase 1

Overview

HepaRegeniX has completed a Phase I trial for HRX-215, with promising results published in the journal Cell. The company is advancing to Phase Ib clinical trial in the US and an international multicenter Phase IIa clinical trial in liver regeneration.

Therapeutic areas: Gastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

darizmetinib

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on HepaRegeniX GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HepaRegeniX GmbH.

Explore the full profile